Literature DB >> 30815174

Disease comorbidity-guided drug repositioning: a case study in schizophrenia.

QuanQiu Wang1, Rong Xu1.   

Abstract

The key to any computational drug repositioning is the availability of relevant data in machine-understandable format. While large amount of genetic, genomic and chemical data are publicly available, large-scale higher-level disease and drug phenotypic data are limited. We recently constructed a large-scale disease-comorbidity relationship knowledge base (dCombKB) and a comprehensive drug-treatment relationship knowledge base (TreatKB) from 21 million biomedical research articles and other resources. In this study, we demonstrated the potential of dCombKB and TreatKB in drug repositioning for schizophrenia, one of the top ten illnesses contributing to the global burden of disease. dCombKB contains 121,359 unique disease-disease comorbidity pairs for 23,041 diseases. TreatKB contains 208,330 unique drug-disease treatment pairs for 2,484 drugs and 24,511 diseases. We constructed a phenotypic comorbidity disease network (PDN) of 14,645 disease nodes and 101,275 edges based on dCombKB. We applied standard network-based ranking algorithm to find diseases that are phenotypically related to SCZ. We developed a drug prioritization system, PhenoPredict-CDN, to systematically reposition drugs for SCZ from diseases phenotypically related to SCZ. PhenoPredict-CDN found all 18 FDA-approved SCZ drugs and ranked them highly as tested in a de-novo validation setting (recall: 1.0, mean ranking: top 6.05%, median ranking: top 1.65%). When compared to PREDICT, a comprehensive drug repositioning system, for novel predictions, Pheno-Predict-CDN outperformed PREDICT in Precision-Recall (PR) curves across three different evaluation datasets. Compared to PREDICT, PhenoPredict-CDN showed a significant 110.0-230.0% improvements in mean average precision. In summary, large-scale higher-level disease-comorbidity relationships data extracted from biomedical literature has potential in drug discovery for SCZ, a complex disease with unknown pathophysiological mechanisms. All the data are publicly available: dCombKB at http://nlp. CASE: edu/public/data/dCombKB, TreatKB at http://nlp. CASE: edu/public/data/treatKB/, and predictions for SCZ at http://nlp. CASE: edu/public/data/SCZ_CDN/.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30815174      PMCID: PMC6371343     

Source DB:  PubMed          Journal:  AMIA Annu Symp Proc        ISSN: 1559-4076


  26 in total

1.  PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery.

Authors:  Rong Xu; QuanQiu Wang
Journal:  J Biomed Inform       Date:  2015-07-04       Impact factor: 6.317

2.  Drug repositioning for prostate cancer: using a data-driven approach to gain new insights.

Authors:  QuanQiu Wang; Rong Xu
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

3.  Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).

Authors:  Rong Xu; Quanqiu Wang
Journal:  J Biomed Inform       Date:  2013-10-28       Impact factor: 6.317

4.  Next-generation treatments for mental disorders.

Authors:  Thomas R Insel
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

5.  Context-sensitive network-based disease genetics prediction and its implications in drug discovery.

Authors:  Yang Chen; Rong Xu
Journal:  Bioinformatics       Date:  2017-04-01       Impact factor: 6.937

Review 6.  In silico methods for drug repurposing and pharmacology.

Authors:  Rachel A Hodos; Brian A Kidd; Khader Shameer; Ben P Readhead; Joel T Dudley
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-04-15

7.  PREDICT: a method for inferring novel drug indications with application to personalized medicine.

Authors:  Assaf Gottlieb; Gideon Y Stein; Eytan Ruppin; Roded Sharan
Journal:  Mol Syst Biol       Date:  2011-06-07       Impact factor: 11.429

8.  Towards understanding brain-gut-microbiome connections in Alzheimer's disease.

Authors:  Rong Xu; QuanQiu Wang
Journal:  BMC Syst Biol       Date:  2016-08-26

9.  Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.

Authors:  A B Nagaraj; Q Q Wang; P Joseph; C Zheng; Y Chen; O Kovalenko; S Singh; A Armstrong; K Resnick; K Zanotti; S Waggoner; R Xu; A DiFeo
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

10.  Explore Small Molecule-induced Genome-wide Transcriptional Profiles for Novel Inflammatory Bowel Disease Drug.

Authors:  Xiaoshu Cai; Yang Chen; Zhen Gao; Rong Xu
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2016-07-20
View more
  3 in total

1.  CoMNRank: An integrated approach to extract and prioritize human microbial metabolites from MEDLINE records.

Authors:  QuanQiu Wang; Rong Xu
Journal:  J Biomed Inform       Date:  2020-08-11       Impact factor: 6.317

2.  Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses.

Authors:  Mengshi Zhou; QuanQiu Wang; Chunlei Zheng; A John Rush; Nora D Volkow; Rong Xu
Journal:  Mol Psychiatry       Date:  2021-01-11       Impact factor: 15.992

3.  The Alzheimer's comorbidity phenome: mining from a large patient database and phenome-driven genetics prediction.

Authors:  Chunlei Zheng; Rong Xu
Journal:  JAMIA Open       Date:  2018-12-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.